Marker Therapeutics, Inc. (MRKR)

2.07 -0.12 (-5.48%) USD  |  NASDAQ  |  Jan 08, 16:00
2.06 -0.01 (-0.48%) After-Hours: 19:44
More

Marker Therapeutics Research and Development Expense (Annual): 13.47M for Dec. 31, 2024

Research and Development Expense (Annual) Chart

View Research and Development Expense (Annual) for MRKR.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (Annual) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
ADMA Biologics, Inc. 1.813M
Neurocrine Biosciences, Inc. 707.60M
AIM ImmunoTech, Inc. 6.149M
Protalix Biotherapeutics, Inc. 12.97M
Armata Pharmaceuticals, Inc. 34.43M